CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study.
about
Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease.The development of animal models of inflammatory bowel disease.Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives.Inflammatory bowel disease: pathogenesis and targets for therapeutic interventions.Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers.Inflammatory bowel disease: new insights into pathogenesis and treatment.Chronic intestinal inflammation and intestinal disease in dogs.Evaluation of new therapies for inflammatory bowel disease.Interleukin 16 expression and phenotype of interleukin 16 producing cells in Crohn's disease.Increased expression of IL-16 in inflammatory bowel diseaseImmunopathogenesis of Crohn's disease.Evolving knowledge and therapy of inflammatory bowel disease.Investigational new drugs in the treatment of inflammatory bowel disease: a review.Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisitaBiologic targeting in the treatment of inflammatory bowel diseases.Origins and functional basis of regulatory CD11c+CD8+ T cells.New pathophysiological insights and modern treatment of IBD.Early years of biological agents therapy in Crohn's disease and risk of the human polyomavirus JC reactivation.New treatments for inflammatory bowel disease.Discovering potential drug-targets for personalized treatment of autoimmune disorders - what we learn from epidermolysis bullosa acquisita.CD4 T cells and major histocompatibility complex class II expression influence worm expulsion and increased intestinal muscle contraction during Trichinella spiralis infection.Higher proliferative capacity of T lymphocytes from patients with Crohn disease than from ulcerative colitis is disclosed by use of Herpesvirus saimiri-transformed T-cell lines.Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.Selective targeting of pro-inflammatory Th1 cells by microRNA-148a-specific antagomirs in vivo.T-bet expression by Th cells promotes type 1 inflammation but is dispensable for colitis.Effector T Helper Cell Subsets in Inflammatory Bowel Diseases.Protein Tyrosine Phosphatases: Regulators of CD4 T Cells in Inflammatory Bowel Disease
P2860
Q33412103-F681EF4A-1F90-4387-B7D5-20C1B86C0D0AQ33867175-2C4E48CA-473B-4817-AA48-2585D3E9A9C7Q34316206-9DA3B2EE-FD11-4C03-9CD2-B74E8A600E3AQ34419021-BA35B401-150C-47FC-97B6-235D269F202DQ34470306-0F0380D3-BBD0-4C5F-8DD8-DFF0C16D7F2DQ35020743-2BD15EC8-42EA-45AC-BB4F-67501EB88EECQ35058836-1B6F4B4B-D418-4516-9C01-138B4B9EC0C8Q35216827-4EB280E1-C593-4A44-813A-1CCD8BC5BD8AQ35366019-248AA419-3754-4A02-8BAC-E7D13E86EBEAQ35565705-0833D4C4-431B-4D44-ACEF-B4F2F090BE70Q36175758-D612A55C-B32C-4B74-8BF2-AF92EEC047BBQ36414506-849C6E40-FE3D-4F20-9978-3D6C4FC31EB9Q36890446-5FE5D373-1DEA-4593-B7E2-A502DCF7F107Q37055162-C232641D-DC83-47C1-8BA6-96DB67B44CB5Q37303206-95BA2618-95B5-4F5B-9ABC-409EC2A8E667Q37356106-E874FDB4-E7B2-4F6E-8C88-7F5C2E3554AFQ37705033-25780994-B9E3-4F1C-B30C-104E3CF51760Q37739997-8BE168D0-B01F-4269-97C8-EA27F01CEDEBQ38634215-18F7FB5C-CD9D-4ABF-9397-B84833BD2A84Q38720806-E41643BB-D0AC-4D8D-9F88-D8B05959E6A4Q39512917-865D19D7-83FD-4B70-9969-23DA1A235F09Q40451943-4A59363C-8A31-43EB-8BE0-C24D80FE2211Q41941349-40B9E2C6-19E8-4214-B82B-5AA6508B601FQ47355591-F7F27BBF-341D-4F89-A5BB-7E71269F8EADQ52855961-87480B9F-FE3A-45D1-BC42-1C8A39C29BDBQ55176161-A2C26548-96F9-4693-B76E-D381BFBF4C94Q59133604-28D43D97-B6E4-4E07-9EF9-6B5E65A359A2
P2860
CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study.
description
1997 nî lūn-bûn
@nan
1997 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի մարտին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
CD4 antibody treatment in pati ...... : a phase 1 dose finding study
@nl
CD4 antibody treatment in pati ...... a phase 1 dose finding study.
@ast
CD4 antibody treatment in pati ...... a phase 1 dose finding study.
@en
CD4 antibody treatment in pati ...... a phase 1 dose finding study.
@en-gb
type
label
CD4 antibody treatment in pati ...... : a phase 1 dose finding study
@nl
CD4 antibody treatment in pati ...... a phase 1 dose finding study.
@ast
CD4 antibody treatment in pati ...... a phase 1 dose finding study.
@en
CD4 antibody treatment in pati ...... a phase 1 dose finding study.
@en-gb
prefLabel
CD4 antibody treatment in pati ...... : a phase 1 dose finding study
@nl
CD4 antibody treatment in pati ...... a phase 1 dose finding study.
@ast
CD4 antibody treatment in pati ...... a phase 1 dose finding study.
@en
CD4 antibody treatment in pati ...... a phase 1 dose finding study.
@en-gb
P2093
P2860
P921
P356
P1433
P1476
CD4 antibody treatment in pati ...... a phase 1 dose finding study.
@en
P2093
Stronkhorst A
ten Berge IJ
van Deventer SJ
P2860
P304
P356
10.1136/GUT.40.3.320
P407
P577
1997-03-01T00:00:00Z